Pharmafile Logo

Glaucoma in perspective

- PMLiVE

Synairgen sinks as AZ halts trial of asthma drug

Results from a phase II trial of inhaled antiviral therapy set to be inconclusive

- PMLiVE

Huntsworth Health appoints Tonic and nitrogen CEOs

Promotes Maryellen Royle and Jon Clark to the top roles

- PMLiVE

MHRA and Swissmedic pledge greater collaboration

Product safety regulators to share information and promote international cooperation

Lucid make the shortlist in all of the four categories they entered for the PMEA programme 2016

The PMEA programme rewards responsible customer-centric business practices that ensure treatments and advice provide patients with meaningful outcomes. The awards have been specifically designed to recognise and commend excellence, best...

Lucid Group Communications Limited

Roche - Basel

Lucentis claims speedy FDA review for myopia complication

Roche’s drug achieved superior visual acuity gains compared to standard treatment in trials

- PMLiVE

At current progress, 2025 Alzheimer’s target ‘unlikely to be reached’

Drug development and diagnosis process requires shake-up to create effective therapies

- PMLiVE

Daniel Beach moves from Ketchum to Portland Health

Becomes part of the senior team as a director

- PMLiVE

Health activators lack confidence in primary healthcare

Survey finds patient decision-makers increasingly turning to non-traditional sources

- PMLiVE

Tesaro’s niraparib threatens Lynparza after acing ovarian cancer trial

Maintenance therapy significantly improved progression-free survival regardless of BRCA status

Bristol-Myers Squibb (BMS) building

Opdivo data confirms poor showing in first-line NSCLC

Lung cancer drug failed to outperform both chemotherapy and Merck & Co’s Keytruda

- PMLiVE

Ipsen eyes first-line licence for new advanced kidney cancer drug Cabometyx

Releases phase II data from head-to-head study with Pfizer's Sutent

- PMLiVE

MHP Communications adds two directors to health unit

Timothy Goodman and Stephanie Snow join

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links